DIEFENBACH KONSTANZE

No ORCID on file · 120 papers in corpus · active 2009-2010
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLAT E FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY.

Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…

2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY